Department of Oncology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Department of Radiation Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
J Cancer Res Ther. 2022 Apr;18(2):399-404. doi: 10.4103/jcrt.jcrt_1965_21.
To reveal the survival and safety of percutaneous microwave ablation (MWA) combined with chemoradiotherapy (CRT) in treating small cell lung cancer (SCLC).
Clinical data of 48 SCLC patients who underwent MWA were retrospectively collected; survival and incidence of major complications were analyzed.
Totally, 48 SCLC patients underwent 51 MWA procedures. The median overall survival (OS) for all SCLC was 27.0 months (95% confidence interval 22.4-31.6 months). The OS of limited-stage (LS-SCLC) was longer than the extensive-stage (ES-SCLC) (median 48.0 months vs. 25.0 months, P = 0.022). The OS of SCLC with tumor diameter ≤3.0 cm was longer than that of tumor diameter >3.0 cm (median 48.0 months vs. 27.0 months, P = 0.041). For LS-SCLC, the 1-, 2-, 3-, and 5-year survival rate was 91.67%, 72.22%, 66.67%, and 61.11%, respectively. For ES-SCLC, the 1-, 2-, and 3-year survival rates were 83.33%, 50.0%, and 8.33%. Major complications included pneumothorax needing tube placement (29.4%), rarely arrhythmia (2.0%), empyema (2.0%), pulmonary fungal infection (2.0%), and shingles (2.0%).
For SCLC patients, who received MWA combined with CRT, OS of LS-SCLC and tumor diameter ≤3.0 cm was better than that of the ES-SCLC and tumor diameter >3.0 cm. For inoperable SCLC, MWA was safe.
揭示经皮微波消融（MWA）联合放化疗（CRT）治疗小细胞肺癌（SCLC）的生存和安全性。
回顾性收集了 48 例接受 MWA 治疗的 SCLC 患者的临床资料；分析了生存和主要并发症的发生率。
共 48 例 SCLC 患者进行了 51 次 MWA 手术。所有 SCLC 的中位总生存期（OS）为 27.0 个月（95%置信区间 22.4-31.6 个月）。局限期（LS-SCLC）的 OS 长于广泛期（ES-SCLC）（中位 48.0 个月比 25.0 个月，P=0.022）。肿瘤直径≤3.0cm 的 SCLC 的 OS 长于肿瘤直径>3.0cm 的 SCLC（中位 48.0 个月比 27.0 个月，P=0.041）。对于 LS-SCLC，1、2、3 和 5 年生存率分别为 91.67%、72.22%、66.67%和 61.11%。对于 ES-SCLC，1、2 和 3 年生存率分别为 83.33%、50.0%和 8.33%。主要并发症包括需要置管的气胸（29.4%）、罕见心律失常（2.0%）、脓胸（2.0%）、肺部真菌感染（2.0%）和带状疱疹（2.0%）。
对于接受 MWA 联合 CRT 的 SCLC 患者，LS-SCLC 和肿瘤直径≤3.0cm 的患者的 OS 优于 ES-SCLC 和肿瘤直径>3.0cm 的患者。对于不能手术的 SCLC，MWA 是安全的。
